ACADIA Pharmaceuticals (ACAD) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[3], including 5 Phase 3[1], 3 Phase 2[2].
Trial NCT06194799[4] evaluates ACP-204 in Alzheimer's Disease Psychosis with a target enrollment of 752 participants. Trial NCT06420297[5] evaluates Carbetocin in Hyperphagia in Prader-Willi Syndrome with a target enrollment of 160 participants. Trial NCT07095465[6] evaluates ACP-204 in Lewy Body Dementia Psychosis with a target enrollment of 126 participants.
ACAD has 8 Form 4 insider filings recorded at the SEC in the past 30 days[7].